[
  {
    "ts": null,
    "headline": "Top Stock Reports for Alphabet, AbbVie & Walt Disney",
    "summary": "GOOGL, ABBV, and DIS face distinct headwinds, but cloud strength, immunology growth, and parks momentum support long-term investor interest.",
    "url": "https://finnhub.io/api/news?id=476dbcc45838d10bf7772e53ed575ed9ef82b9507fb01ed40441a6088f59116a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751401860,
      "headline": "Top Stock Reports for Alphabet, AbbVie & Walt Disney",
      "id": 135699818,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "GOOGL, ABBV, and DIS face distinct headwinds, but cloud strength, immunology growth, and parks momentum support long-term investor interest.",
      "url": "https://finnhub.io/api/news?id=476dbcc45838d10bf7772e53ed575ed9ef82b9507fb01ed40441a6088f59116a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=e1754b057c4bb13891df333c956f0fa4792763a932260c47d728a2c11a2bfd27",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751387460,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 135729909,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=e1754b057c4bb13891df333c956f0fa4792763a932260c47d728a2c11a2bfd27"
    }
  },
  {
    "ts": null,
    "headline": "LENZ Therapeutics: Presbyopia Eyedrops Look Promising",
    "summary": "LENZ Therapeutics' aceclidine outshines Vuity for presbyopia with better safety and duration. Click for LENZ's market potential and revenue growth forecast.",
    "url": "https://finnhub.io/api/news?id=c91ed1b231687100ab5410f2fd6b09fb4272a7b6c24a001695b7d92668bc5a2d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751387039,
      "headline": "LENZ Therapeutics: Presbyopia Eyedrops Look Promising",
      "id": 135697622,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1306234498/image_1306234498.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "LENZ Therapeutics' aceclidine outshines Vuity for presbyopia with better safety and duration. Click for LENZ's market potential and revenue growth forecast.",
      "url": "https://finnhub.io/api/news?id=c91ed1b231687100ab5410f2fd6b09fb4272a7b6c24a001695b7d92668bc5a2d"
    }
  },
  {
    "ts": null,
    "headline": "ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B",
    "summary": "AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.",
    "url": "https://finnhub.io/api/news?id=038f3149867243794d45f9c39b07101eb61f4e8885ed969399951957c4c82242",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751378700,
      "headline": "ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B",
      "id": 135693977,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.",
      "url": "https://finnhub.io/api/news?id=038f3149867243794d45f9c39b07101eb61f4e8885ed969399951957c4c82242"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Yield Theory Says Merck Is A Buy",
    "summary": "Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis of MRK stock now.",
    "url": "https://finnhub.io/api/news?id=834f6c41a13ef01ef32430679fea68a13c91eade7633e28e61c1eacc094f648c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751378260,
      "headline": "Dividend Yield Theory Says Merck Is A Buy",
      "id": 135696430,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190227480/image_2190227480.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis of MRK stock now.",
      "url": "https://finnhub.io/api/news?id=834f6c41a13ef01ef32430679fea68a13c91eade7633e28e61c1eacc094f648c"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?",
    "summary": "Sector ETF report for FHLC",
    "url": "https://finnhub.io/api/news?id=2bb96508dd28b29f360489c0f4247aefc4d31170870fba8c025ac3c486b232c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751365206,
      "headline": "Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?",
      "id": 135693887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Sector ETF report for FHLC",
      "url": "https://finnhub.io/api/news?id=2bb96508dd28b29f360489c0f4247aefc4d31170870fba8c025ac3c486b232c3"
    }
  },
  {
    "ts": null,
    "headline": "2025 H1 Portfolio Review: More Ways To Win",
    "summary": "My portfolio outperformed the S&P 500 as I deployed a larger than normal amount of cash into new trades. I remain cautiously bullish for H2 2025, expecting stronger returns ahead.",
    "url": "https://finnhub.io/api/news?id=faab322b62d649042f0f31e10e6fc1354ad62706798b8401f6c55695960e7239",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751358518,
      "headline": "2025 H1 Portfolio Review: More Ways To Win",
      "id": 135689691,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148704520/image_2148704520.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "My portfolio outperformed the S&P 500 as I deployed a larger than normal amount of cash into new trades. I remain cautiously bullish for H2 2025, expecting stronger returns ahead.",
      "url": "https://finnhub.io/api/news?id=faab322b62d649042f0f31e10e6fc1354ad62706798b8401f6c55695960e7239"
    }
  }
]